Remove 2028 Remove Leads Remove Physicians
article thumbnail

Improving Patient-Physician Interaction with AI-Enhanced Data

PM360

However, maintaining meaningful interactions between patients and physicians has become increasingly challenging amid the complexities of clinical data management and modern medical practice demands, impacting patient satisfaction, trust, and healthcare outcomes. million by 2028.

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. Checkpoint modulators and cell therapies lead the way in the pre-registration stage, which features no cancer vaccines and oncolytic virus-focused therapies, she added.

Marketing 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively.

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

article thumbnail

Your Guide to Virtual Reality Reimbursement in the U.S. Healthcare Market

Nixon Gwilt Law

CMS and other payors do not currently pay for these codes , but billing practitioners should continue to submit claims including the codes to provide necessary information that will hopefully lead to more reimbursement opportunities for VR in the future. Telehealth. Remote Therapeutic Monitoring (“RTM”).

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

In 2023, Humana’s care delivery component CenterWell launched a senior-centered “ Primary Care Anywhere ” program for in-home primary care in Georgia and Louisiana (where Humana leads the MA sectors) and increased senior membership in value-based home care models nationwide to more than 840,000.

Retail 52